Premium
Drug repurposing approach to combating coronavirus: Potential drugs and drug targets
Author(s) -
Xu Jimin,
Xue Yu,
Zhou Richard,
Shi PeiYong,
Li Hongmin,
Zhou Jia
Publication year - 2021
Publication title -
medicinal research reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.868
H-Index - 130
eISSN - 1098-1128
pISSN - 0198-6325
DOI - 10.1002/med.21763
Subject(s) - drug repositioning , repurposing , pandemic , coronavirus , medicine , drug , middle east respiratory syndrome coronavirus , covid-19 , intensive care medicine , drug development , approved drug , disease , middle east respiratory syndrome , infectious disease (medical specialty) , pharmacology , biology , ecology
In the past two decades, three highly pathogenic human coronaviruses severe acute respiratory syndrome coronavirus (SARS‐CoV), Middle East respiratory syndrome coronavirus, and, recently, SARS‐CoV‐2, have caused pandemics of severe acute respiratory diseases with alarming morbidity and mortality. Due to the lack of specific anti‐CoV therapies, the ongoing pandemic of coronavirus disease 2019 (COVID‐19) poses a great challenge to clinical management and highlights an urgent need for effective interventions. Drug repurposing is a rapid and feasible strategy to identify effective drugs for combating this deadly infection. In this review, we summarize the therapeutic CoV targets, focus on the existing small molecule drugs that have the potential to be repurposed for existing and emerging CoV infections of the future, and discuss the clinical progress of developing small molecule drugs for COVID‐19.